LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article ; Online: Applying interpretable machine learning workflow to evaluate exposure-response relationships for large-molecule oncology drugs.

    Liu, Gengbo / Lu, James / Lim, Hong Seo / Jin, Jin Yan / Lu, Dan

    CPT: pharmacometrics & systems pharmacology

    2022  Volume 11, Issue 12, Page(s) 1614–1627

    Abstract: The application of logistic regression (LR) and Cox Proportional Hazard (CoxPH) models are well-established for evaluating exposure-response (E-R) relationship in large molecule oncology drugs. However, applying machine learning (ML) models on evaluating ...

    Abstract The application of logistic regression (LR) and Cox Proportional Hazard (CoxPH) models are well-established for evaluating exposure-response (E-R) relationship in large molecule oncology drugs. However, applying machine learning (ML) models on evaluating E-R relationships has not been widely explored. We developed a workflow to train regularized LR/CoxPH and tree-based XGboost (XGB) models, and derive the odds ratios for best overall response and hazard ratios for overall survival, across exposure quantiles to evaluate the E-R relationship using clinical trial datasets. The E-R conclusions between LR/CoxPH and XGB models are overall consistent, and largely aligned with historical pharmacometric analyses findings. Overall, applying this interpretable ML workflow provides a promising alternative method to assess E-R relationships for impacting key dosing decisions in drug development.
    MeSH term(s) Humans ; Workflow ; Machine Learning ; Logistic Models ; Proportional Hazards Models
    Language English
    Publishing date 2022-10-20
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2697010-7
    ISSN 2163-8306 ; 2163-8306
    ISSN (online) 2163-8306
    ISSN 2163-8306
    DOI 10.1002/psp4.12871
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Crystal structure of (4-fluorophenyl-κC1)iodido(N,N,N′,N′-tetramethylethylenediamine-κ2N,N′)palladium(II)

    Jin-Jin Yan / Chang-Ge Zheng

    Acta Crystallographica Section E: Crystallographic Communications, Vol 71, Iss 5, Pp m124-m

    2015  Volume 125

    Abstract: In the title compound, [Pd(C6H4F)I(C6H16N2)], the PdII atom is coordinated by two N atoms from the N,N,N′,N′-tetramethylethylenediamine ligand, a C atom of the 4-fluorophenyl group and an iodide ligand in a distorted square-planar geometry, with an ... ...

    Abstract In the title compound, [Pd(C6H4F)I(C6H16N2)], the PdII atom is coordinated by two N atoms from the N,N,N′,N′-tetramethylethylenediamine ligand, a C atom of the 4-fluorophenyl group and an iodide ligand in a distorted square-planar geometry, with an average deviation from the least-squares plane through the ligand donor atoms of 0.0159 (2) Å. The angles about the PdII atom range from 83.35 (16) to 178.59 (11)°. In the crystal, weak C—H.F and C—H.I hydrogen bonds link the molecules into sheets in the bc plane.
    Keywords crystal structure ; palladium(II) complex ; tetramethylethylenediamine ; square-planar coordination ; single-crystal X-ray study ; hydrogen bonding ; Chemistry ; QD1-999
    Language English
    Publishing date 2015-05-01T00:00:00Z
    Publisher International Union of Crystallography
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.

    Lu, Dan / Lu, Tong / Shi, Rong / Gibiansky, Leonid / Agarwal, Priya / Shemesh, Colby S / Dere, Randall C / Ogbu, Uzor / Hirata, Jamie / Chanu, Pascal / Girish, Sandhya / Jin, Jin Yan / Li, Chunze / Miles, Dale

    Pharmaceutical research

    2020  Volume 37, Issue 12, Page(s) 252

    Abstract: Purpose: The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) ... ...

    Abstract Purpose: The established two-analyte integrated population pharmacokinetic model was applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of polatuzumab vedotin (pola) in patients with non-Hodgkin lymphoma (NHL) following bodyweight-based dosing.
    Methods: Model simulations based on individual empirical Bayes estimates were used to evaluate the impact of intrinsic/extrinsic factors as patient subgroups on Cycle 6 exposures. Intrinsic factors included bodyweight, age, sex, hepatic and renal functions. Extrinsic factors included rituximab/obinutuzumab or bendamustine combination with pola and manufacturing process. The predicted impact on exposures along with the established exposure-response relationships were used to assess clinical relevance.
    Results: No clinically meaningful differences in Cycle 6 pola exposures were found for the following subgroups: bodyweight 100-146 kg versus 38-<100 kg, age ≥ 65 years versus <65 years, female versus male, mild hepatic impairment versus normal, mild-to-moderate renal impairment versus normal. Co-administration of rituximab/obinutuzumab or bendamustine, and change in the pola manufacturing process, also had no meaningful impact on PK.
    Conclusions: In patients with NHL, bodyweight-based dosing is adequate, and no further dose adjustment is recommended for the heavier subgroup (100-146 kg). In addition, no dose adjustments are recommended for other subgroups based on intrinsic/extrinsic factors evaluated.
    MeSH term(s) Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/pharmacokinetics ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacokinetics ; Body Weight ; Clinical Trials as Topic ; Computer Simulation ; Drug Dosage Calculations ; Female ; Humans ; Immunoconjugates/administration & dosage ; Immunoconjugates/pharmacokinetics ; Lymphoma, Non-Hodgkin/drug therapy ; Male ; Middle Aged ; Models, Biological ; Sex Factors ; Young Adult
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents, Immunological ; Immunoconjugates ; polatuzumab vedotin (KG6VO684Z6)
    Language English
    Publishing date 2020-12-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 843063-9
    ISSN 1573-904X ; 0724-8741 ; 0739-0742
    ISSN (online) 1573-904X
    ISSN 0724-8741 ; 0739-0742
    DOI 10.1007/s11095-020-02933-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.

    Lu, Tong / Gibiansky, Leonid / Li, Xiaobin / Li, Chunze / Shi, Rong / Agarwal, Priya / Hirata, Jamie / Miles, Dale / Chanu, Pascal / Girish, Sandhya / Jin, Jin Yan / Lu, Dan

    Leukemia & lymphoma

    2020  Volume 61, Issue 12, Page(s) 2905–2914

    Abstract: Exposure-response relationships were investigated to assess the risk/benefit of polatuzumab vedotin (pola) + bendamustine-rituximab (pola + BR) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Analyses were conducted in pivotal study ... ...

    Abstract Exposure-response relationships were investigated to assess the risk/benefit of polatuzumab vedotin (pola) + bendamustine-rituximab (pola + BR) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Analyses were conducted in pivotal study GO29365 (NCT02257567; BR/pola + BR/pola + BG [BG: bendamustine-obinutuzumab]; 1.8 mg/kg pola, every 3 weeks [Q3W], six cycles), and supportive studies DCS4968g (NCT01290549) and GO27834 (NCT01691898) (pola/pola + R/pola + G; 0.1-2.4 mg/kg pola Q3W; eight-cycle landmark), separately. Exposure was characterized as simulated cycle-6 AUC and
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Humans ; Immunoconjugates/adverse effects ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Non-Hodgkin/drug therapy
    Chemical Substances Antibodies, Monoclonal ; Immunoconjugates ; polatuzumab vedotin (KG6VO684Z6)
    Language English
    Publishing date 2020-07-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2020.1795154
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions.

    Chen, Yuan / Ma, Fang / Jones, Nicholas S / Yoshida, Kenta / Chiang, Po-Chang / Durk, Matthew R / Wright, Matthew R / Jin, Jin Yan / Chinn, Leslie W

    CPT: pharmacometrics & systems pharmacology

    2020  Volume 9, Issue 6, Page(s) 332–341

    Abstract: Fenebrutinib is a CYP3A substrate and time-dependent inhibitor, as well as a BCRP and OATP1B transporter inhibitor in vitro. Physiologically-based pharmacokinetic (PBPK) modeling strategies with the ultimate goal of understanding complex drug-drug ... ...

    Abstract Fenebrutinib is a CYP3A substrate and time-dependent inhibitor, as well as a BCRP and OATP1B transporter inhibitor in vitro. Physiologically-based pharmacokinetic (PBPK) modeling strategies with the ultimate goal of understanding complex drug-drug interactions (DDIs) and proposing doses for untested scenarios were developed. The consistency in the results of two independent approaches, PBPK simulation and endogenous biomarker measurement, supported that the observed transporter DDI is primarily due to fenebrutinib inhibition of intestinal BCRP, rather than hepatic OATP1B. A mechanistic-absorption model accounting for the effects of excipient complexation with fenebrutinib was used to rationalize the unexpected observation of itraconazole-fenebrutinib DDI (maximum plasma concentration (C
    MeSH term(s) ATP Binding Cassette Transporter, Subfamily G, Member 2/antagonists & inhibitors ; ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism ; Animals ; Biotransformation ; Clinical Trials, Phase I as Topic ; Computer Simulation ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Cytochrome P-450 CYP3A Inhibitors/chemistry ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics ; Dogs ; Drug Compounding ; Drug Development ; Drug Interactions ; Excipients/chemistry ; Humans ; Intestines/drug effects ; Liver/drug effects ; Liver/metabolism ; Liver-Specific Organic Anion Transporter 1/antagonists & inhibitors ; Liver-Specific Organic Anion Transporter 1/metabolism ; Madin Darby Canine Kidney Cells ; Models, Biological ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/metabolism ; Piperazines/adverse effects ; Piperazines/chemistry ; Piperazines/pharmacokinetics ; Pyridones/adverse effects ; Pyridones/chemistry ; Pyridones/pharmacokinetics ; Retrospective Studies
    Chemical Substances ABCG2 protein, human ; ATP Binding Cassette Transporter, Subfamily G, Member 2 ; Cytochrome P-450 CYP3A Inhibitors ; Excipients ; Liver-Specific Organic Anion Transporter 1 ; Neoplasm Proteins ; Piperazines ; Pyridones ; SLCO1B1 protein, human ; fenebrutinib (E9L2885WUL) ; CYP3A protein, human (EC 1.14.14.1) ; Cytochrome P-450 CYP3A (EC 1.14.14.1)
    Language English
    Publishing date 2020-05-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2697010-7
    ISSN 2163-8306 ; 2163-8306
    ISSN (online) 2163-8306
    ISSN 2163-8306
    DOI 10.1002/psp4.12515
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

    Shi, Rong / Lu, Tong / Ku, Grace / Ding, Hao / Saito, Tomohisa / Gibiansky, Leonid / Agarwal, Priya / Li, Xiaobin / Jin, Jin Yan / Girish, Sandhya / Miles, Dale / Li, Chunze / Lu, Dan

    Cancer chemotherapy and pharmacology

    2020  Volume 86, Issue 3, Page(s) 347–359

    Abstract: Purpose: The CD79b-targeted antibody-drug conjugate polatuzumab vedotin (pola), alone and with chemoimmunotherapy, has clinical efficacy and a tolerable safety profile in B-cell non-Hodgkin lymphoma (B-NHL). We assessed (a) whether exposure from global ... ...

    Abstract Purpose: The CD79b-targeted antibody-drug conjugate polatuzumab vedotin (pola), alone and with chemoimmunotherapy, has clinical efficacy and a tolerable safety profile in B-cell non-Hodgkin lymphoma (B-NHL). We assessed (a) whether exposure from global studies of pola is comparable to Asian patients, and (b) if the recommended pola dose is appropriate in Asian patients based on exposure.
    Methods: The pharmacokinetics (PK) of pola in Asian and global populations was characterized for three analytes (antibody-conjugated monomethyl auristatin E (MMAE) [acMMAE], total antibody, and unconjugated MMAE) in five phase 1b/2 single-agent and combination studies in B-NHL patients (JO29138 [JAPICCTI-142580], DCS4968g [NCT01290549], GO27834 [NCT01691898], GO29044 [NCT01992653], and GO29365 [NCT02257567]). PK data were compared between Japanese phase 1 JO29138 (JAPICCTI-142580) and global phase 1 DCS4968g (NCT01290549) studies and between Asian and non-Asian patients in the randomized relapsed/refractory B-NHL cohorts of the phase 1b/2 study GO29365 (NCT02257567). A population PK (popPK) model was used to assess the effects of Asian race and region on acMMAE and unconjugated MMAE exposure.
    Results: PK non-compartmental analysis (NCA) parameters for the key analyte acMMAE in the Japanese JO29138 (JAPICCTI-142580) and global phase 1 DCS4968g (NCT01290549) studies were similar. In GO29365 (NCT02257567), the phase 1b/2 combination study, mean exposure to the analytes was generally lower in Asian patients (by ~ 9.9 to 17.5%), but not to a clinically meaningful extent. Overall, the popPK model further suggested comparable PK in Asian patients with B-NHL (race or region) versus non-Asian patients.
    Conclusion: Race has no clinically meaningful effect on pola PK. These results (and observations from efficacy/safety exposure-response analyses) support no pola dose adjustments are warranted for Asian patients with DLBCL.
    MeSH term(s) Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/pharmacokinetics ; Asian People/statistics & numerical data ; CD79 Antigens/immunology ; Drug Resistance, Neoplasm ; Follow-Up Studies ; Humans ; Immunoconjugates/administration & dosage ; Immunoconjugates/pharmacokinetics ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/ethnology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/ethnology ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Salvage Therapy ; Survival Rate ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; CD79 Antigens ; CD79B protein, human ; Immunoconjugates ; polatuzumab vedotin (KG6VO684Z6)
    Language English
    Publishing date 2020-08-08
    Publishing country Germany
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-020-04119-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.

    Zhu, Rui / Lu, Dan / Chu, Yu-Waye / Chai, Akiko / Green, Michelle / Zhang, Nancy / Jin, Jin Yan

    The AAPS journal

    2017  Volume 19, Issue 3, Page(s) 669–681

    Abstract: Correlations between early and late efficacy endpoints were assessed to identify potential surrogate endpoints for overall survival (OS) or progression-free survival (PFS) with clinical trial-level data in three non-Hodgkin lymphoma (NHL) subtypes: ... ...

    Abstract Correlations between early and late efficacy endpoints were assessed to identify potential surrogate endpoints for overall survival (OS) or progression-free survival (PFS) with clinical trial-level data in three non-Hodgkin lymphoma (NHL) subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). One hundred and eight phase II-III trials (129 trial arms) in DLBCL, FL, and MCL were identified and included in the database. Correlations between efficacy endpoints were analyzed using weighted linear regression and Pearson's coefficient of determination (R
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Disease-Free Survival ; Humans ; Lymphoma, Non-Hodgkin/drug therapy ; Outcome Assessment (Health Care)
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2017-02-21
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Review ; Research Support, Non-U.S. Gov't
    ISSN 1550-7416
    ISSN (online) 1550-7416
    DOI 10.1208/s12248-017-0056-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.

    Lu, Dan / Lu, Tong / Gibiansky, Leonid / Li, Xiaobin / Li, Chunze / Agarwal, Priya / Shemesh, Colby S / Shi, Rong / Dere, Randall C / Hirata, Jamie / Miles, Dale / Chanu, Pascal / Girish, Sandhya / Jin, Jin Yan

    CPT: pharmacometrics & systems pharmacology

    2019  Volume 9, Issue 1, Page(s) 48–59

    Abstract: A two-analyte integrated population pharmacokinetic (PK) model that simultaneously describes concentrations of antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE following repeated administrations of polatuzumab vedotin (pola) was ...

    Abstract A two-analyte integrated population pharmacokinetic (PK) model that simultaneously describes concentrations of antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE following repeated administrations of polatuzumab vedotin (pola) was developed based on data from four clinical studies of pola in patients with non-Hodgkin lymphoma. A two-compartment model with a nonspecific, time-dependent linear clearance, a linear time-dependent exponentially declining clearance, and a Michaelis-Menten clearance provided a good fit of the acMMAE plasma PK profiles. All three acMMAE elimination pathways contributed to the input to the central compartment of unconjugated MMAE, which was also described by a two-compartment model. Population PK parameters, covariate effects, and interindividual variability of model parameters were estimated. The impact of clinically relevant covariates on PK exposures of each analyte were quantified and reported to support key label claims.
    MeSH term(s) Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/pharmacokinetics ; Clinical Trials as Topic ; Humans ; Immunoconjugates/administration & dosage ; Immunoconjugates/pharmacokinetics ; Linear Models ; Lymphoma, Non-Hodgkin/drug therapy ; Models, Biological ; Time Factors
    Chemical Substances Antibodies, Monoclonal ; Immunoconjugates ; polatuzumab vedotin (KG6VO684Z6)
    Language English
    Publishing date 2019-12-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2697010-7
    ISSN 2163-8306 ; 2163-8306
    ISSN (online) 2163-8306
    ISSN 2163-8306
    DOI 10.1002/psp4.12482
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.

    Lu, Dan / Li, Chunze / Riggs, Matthew / Polhamus, Daniel / French, Jonathan / Agarwal, Priya / Chen, Shang-Chiung / Vadhavkar, Shweta / Patre, Monika / Strasak, Alexander / Quartino, Angelica / Jin, Jin Yan / Girish, Sandhya

    Cancer chemotherapy and pharmacology

    2019  Volume 84, Issue 1, Page(s) 175–185

    Abstract: Purpose: The phase III MARIANNE study investigated single-agent trastuzumab emtansine (T-DM1) and combination T-DM1 plus pertuzumab as the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). ... ...

    Abstract Purpose: The phase III MARIANNE study investigated single-agent trastuzumab emtansine (T-DM1) and combination T-DM1 plus pertuzumab as the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Pharmacokinetic properties of T-DM1 and pertuzumab in these patients and the potential for drug-drug interactions (DDIs) were assessed.
    Methods: Pharmacokinetic samples of T-DM1-related analytes (T-DM1 conjugate, total trastuzumab, DM1) and pertuzumab were analyzed. Observed pharmacokinetic data were summarized for all analytes. Historical population pharmacokinetic models for T-DM1 conjugate and pertuzumab in HER2-positive MBC were used to derive empirical Bayes estimates of pharmacokinetic parameters.
    Results: In MARIANNE (N = 375), mean ± standard deviation population pharmacokinetic model-predicted Cycle 1 C
    Conclusions: Based on the population pharmacokinetic analysis of T-DM1 conjugate and pertuzumab, pharmacokinetics are similar across different lines of treatment and stages of disease including previously untreated MBC patients, and no DDIs were identified for combined use of T-DM1 and pertuzumab.
    MeSH term(s) Ado-Trastuzumab Emtansine/administration & dosage ; Ado-Trastuzumab Emtansine/pharmacokinetics ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Area Under Curve ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Drug Interactions ; Female ; Humans ; Models, Biological ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Receptor, ErbB-2/metabolism
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; pertuzumab (K16AIQ8CTM) ; Ado-Trastuzumab Emtansine (SE2KH7T06F)
    Language English
    Publishing date 2019-05-17
    Publishing country Germany
    Document type Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 6820-2
    ISSN 1432-0843 ; 0344-5704 ; 0943-9404
    ISSN (online) 1432-0843
    ISSN 0344-5704 ; 0943-9404
    DOI 10.1007/s00280-019-03852-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.

    Zhu, Rui / Poland, Bill / Wada, Russ / Liu, Qi / Musib, Luna / Maslyar, Daniel / Cho, Eunpi / Yu, Wei / Ma, Han / Jin, Jin Yan / Budha, Nageshwar

    CPT: pharmacometrics & systems pharmacology

    2019  Volume 8, Issue 4, Page(s) 240–248

    Abstract: The aims of this work were to characterize ipatasertib exposure-response (E-R) relationships in a phase II study and to quantitatively assess benefit-risk using a clinical utility index approach to support ipatasertib phase III dose selection in patients ...

    Abstract The aims of this work were to characterize ipatasertib exposure-response (E-R) relationships in a phase II study and to quantitatively assess benefit-risk using a clinical utility index approach to support ipatasertib phase III dose selection in patients with metastatic castration-resistant prostate cancer. Logistic regression and Cox proportional-hazards models characterized E-R relationships for safety and efficacy endpoints, respectively. Exposure metrics with and without considering dose interruptions/reductions (modifications) were tested in the E-R models. Despite a steeper E-R relationship when accounting for dose modifications, similar dose-response projections were generated. The clinical utility index analysis assessed important attributes, weights, and clinically meaningful cutoff/tradeoff values based on predefined minimal, target, and optimistic product profiles. Ipatasertib 400 mg daily, showing the highest probability of achieving the minimal product profiles and better benefit-risk balance than other doses (200-500 mg daily), was selected for further development in metastatic castration-resistant prostate cancer.
    MeSH term(s) Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Drug Administration Schedule ; Drug Dosage Calculations ; Humans ; Logistic Models ; Male ; Models, Theoretical ; Piperazines/administration & dosage ; Piperazines/adverse effects ; Piperazines/pharmacokinetics ; Proportional Hazards Models ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics
    Chemical Substances Antineoplastic Agents ; Piperazines ; Pyrimidines ; ipatasertib (524Y3IB4HQ)
    Language English
    Publishing date 2019-03-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2697010-7
    ISSN 2163-8306 ; 2163-8306
    ISSN (online) 2163-8306
    ISSN 2163-8306
    DOI 10.1002/psp4.12394
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top